Melphalan pharmacokinetics and transplant related toxicity during autologous stem cell transplantation

Bone Marrow Transplant. 2021 Jan;56(1):7-8. doi: 10.1038/s41409-020-01043-6. Epub 2020 Aug 26.

Authors

Ugur Sahin¹, Ender Soydan², Ayla Gokmen², Muhit Ozcan³, Onder Arslan³

Affiliations

¹ Hematology and Bone Marrow Transplantation Unit, Medicana International Ankara Hospital, Ankara, Turkey. ugursahin_dr@yahoo.com.
² Hematology and Bone Marrow Transplantation Unit, Medicana International Ankara Hospital, Ankara, Turkey.
³ Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey.

PMID: 32848191
DOI: 10.1038/s41409-020-01043-6

No abstract available

Publication types

Comment

MeSH terms

Amyloidosis*
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Melphalan / adverse effects
Multiple Myeloma* / therapy
Transplantation Conditioning
Transplantation, Autologous

Substances

Melphalan